ClinicalTrials.gov
public full text
Public Domain
A First Time In Human Study To Assess The Compound GSK615915
GSK615915A is being developed as a novel surfactant for use in the formulation of GSK's future generation of Metered Dose Inhalers (MDIs). A surfactant in a MDI would provide a more stable drug suspension, this in turn will produce a consistent dose of drug being delivered with each puff.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- GSK2190915 Safety and Pharmacokinetic Study in Healthy Japanese Subjects#1124933
- Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC#898631
- Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET#908272
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.#1075104
- UJI AKTIVITAS ANTIOKSIDAN EKSTRAK ETANOL KLIKA FALOAK (Sterculia quadrifida R.Br) DENGAN METODE DPPH (2,2-diphenyl-1-picrylhydrazyl)#932837
Record · ID 1410005
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive